Abstract:Objective: We sought to identify tumor necrosis factor (TNF)-alpha-induced protein 8-like 2 (TIPE2/TNFAIP8L2) expression in bladder cancer and its relationship to clinicopathological findings and prognosis.Methods: Immunohistochemical (IHC) staining for TIPE2 was performed on 110 archived radical cystectomy specimens. Ten high-power fields were randomly selected from each specimen to observe and record the percentage of immunoreactive cells of TIPE2 in tumor cells (grade 0-4) and the corresponding immunostaining intensity (grade 0-3). The expression score of TIPE2 was obtained by multiplying the results of the above two scores, which ranged from 0 to 12 points. The cut-off point of the sum of the scores were defined as follows: 0-3 scores were defined as negative expression (-); >3 scores were classified as positive expression, < 7, low expression, >= 7, high expression.Results: In 110 cases, TIPE2 was stained in various degrees in bladder cancer tissues, and expressed in both nucleus and cytoplasm. 4.5% (5/110) showed negative expression, 40.9% (45/110) showed low expression, and 54.5% (60/110) showed high expression. TIPE2 expression was negatively correlated with lymph node metastasis (p = 0.004) and disease progression (p = 0.021). Survival curves were plotted to show that patients with high TIPE2 expression had a progression-free survival curve above those with negative/low TIPE2 expression (p = 0.027). In multivariate Cox proportional hazard regression analysis, TIPE2 was a protective factor for progression-free survival in bladder urothelial carcinoma (p = 0.031), pT stage (p = 0.016) was a risk factor for progression-free survival, and age was a risk factor for overall survival (p = 0.020).Conclusion: TIPE2 may be a new biomarker to predict the disease progression and prognosis of patients with urothelial carcinoma of the bladder.

Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies.

TIPE2: A Candidate for Targeting Antitumor Immunotherapy.

A Novel Prognostic Factor TIPE2 Inhibits Cell Proliferation and Promotes Apoptosis in Pancreatic Ductal Adenocarcinoma (PDAC)

Update in Immune Regulatory Pathway of Tumor Necrosis Factor-Α-induced Protein 8-Like 2

Tumor Necrosis Factor (Tnf)-Α-induced Protein 8-Like-2 (TIPE2) Inhibits Proliferation and Tumorigenesis in Breast Cancer Cells.

A Novel Prognostic Factor TIPE2 in Bladder Cancer

Regulatory Roles of Tumor Necrosis Factor-α-Induced Protein 8 Like-Protein 2 in Inflammation, Immunity and Cancers: A Review

Research progress of TIPE2 in immune-related diseases

Understanding the roles of negative immune regulator TIPE2 in different diseases and tumourigenesis.

A Pan-Cancer Analysis Revealing the Role 2 of TIGIT in Tumor Microenvironment

Checkpoint TIPE2 Limits the Helper Functions of NK Cells in Supporting Antitumor CD8+ T Cells

In Silico and in Vivo Analysis of TIPE1 Expression in Diffuse Large B Cell Lymphoma

Novel tumor necrosis factor-α induced protein eight (TNFAIP8/TIPE) family: Functions and downstream targets involved in cancer progression

Tumor Immune Checkpoints and Their Associated Inhibitors

Oncogenic Role of Tumor Necrosis Factor α-Induced Protein 8 (TNFAIP8)

Effect of Tumor Necrosis Factor-Α Induced Protein 8 Like-2 on Immune Function of Dendritic Cells in Mice Following Acute Insults

TIPE1 function as a prognosis predictor and negative regulator of lung cancer

The epiphany derived from T-cell-inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses

TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments

TIPE2 is a Checkpoint of Natural Killer Cell Maturation and Antitumor Immunity